PANBELA THERAPEUTICS INC (PBLA)

US69833W4042 - Common Stock

1.11  -0.12 (-9.76%)

After market: 1.04 -0.07 (-6.31%)

News Image
4 days ago - InvestorPlace

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024

PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

News Image
4 days ago - BusinessInsider

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the first quarter ...

News Image
a month ago - Panbela Therapeutics, Inc.

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Trial's lower-than-expected event rate suggests improved survival outcomes

News Image
a month ago - Panbela Therapeutics, Inc.

Panbela Announces Poster Presentation at American Association for Cancer Research:

Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models 

News Image
a month ago - Panbela Therapeutics, Inc.

Panbela Announces Transfer to OTCQB Market

News Image
2 months ago - InvestorPlace

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023

PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - BusinessInsider

PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the fourth quarter...

News Image
2 months ago - Panbela Therapeutics, Inc.

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...

News Image
3 months ago - Seeking Alpha

Panbela Therapeutics regains compliance with Nasdaq (NASDAQ:PBLA)

Panbela Therapeutics (PBLA) regains compliance with Nasdaq for bid price and publicly held shares, marking a positive development for the clinical stage...

News Image
4 months ago - Seeking Alpha

Panbela Therapeutics closes ~$9M public offering of shares (NASDAQ:PBLA)

Biopharmaceutical company Panbela Therapeutics has closed ~$9M public offering of ~4.4M shares priced at $2.06 per share.

News Image
4 months ago - Panbela Therapeutics, Inc.

Panbela Announces Closing of Approximately $9.0 Million Public Offering

MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

News Image
4 months ago - Panbela Therapeutics, Inc.

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

News Image
4 months ago - InvestorPlace

Why Is Aclarion (ACON) Stock Down 16% Today?

Aclarion stock is falling on Monday after the company issued 500,000 shares of ACON to cover principal and accrued interest from notes.

News Image
4 months ago - InvestorPlace

Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?

Panbela Therapeutics stock is falling on Monday after pricing a public offering for PBLA shares well below its price closing price.

News Image
4 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!

News Image
4 months ago - Seeking Alpha

Panbela Therapeutics stock drops on stock offer (NASDAQ:PBLA)

Panbela Therapeutics (PBLA) stock lost ~62% in value after announcing a public offering to raise approximately $9.0M in gross proceeds. Read more here.

News Image
4 months ago - Panbela Therapeutics, Inc.

Panbela Announces Pricing of Approximately $9.0 Million Public Offering

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...